肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
3期
223-226
,共4页
柴胡疏肝散%化疗%乳腺癌
柴鬍疏肝散%化療%乳腺癌
시호소간산%화료%유선암
Chaihu-Shugang-San%Chemotherapy%Breast cancer
目的观察柴胡疏肝散联合化疗治疗乳腺癌的临床疗效。方法选择2009年1月～2009年10月在我科住院治疗的57例乳腺癌患者，随机分成两组，对照组按NP方案化疗，治疗组在化疗的基础上再给予柴胡疏肝散治疗。3周为1个疗程，至少治疗2个疗程后评价和比较两组的临床疗效、不良反应的发生情况以及患者的预后。结果治疗组乳腺癌软组织转移、肝转移乳腺癌、肺转移乳腺癌、骨转移乳腺癌的治疗有效率（RR）分别为43.3%、6.7%、13.3%、3.3%；对照组的治疗有效率（RR）依次分别为29.6%、3.7%、7.4%、3.7%，治疗组软组织转移乳腺癌与肺转移乳腺癌治疗有效率与对照组相比显著升高，差异有统计学意义（P=0.046）。治疗组白细胞减少、血红蛋白降低、红细胞减少以及血小板减少的发生率均显著低于对照组，差异具有统计学意义（P<0.05）。两组患者治疗后6、12、18、24、30、36个月的生存率比较，差异均无统计学意义（P>0.05）。结论柴胡疏肝散NP方案治疗乳腺癌能提高软组织转移乳腺癌与肺转移乳腺癌的临床疗效，并减轻化疗所致的毒副反应，值得临床推广应用。
目的觀察柴鬍疏肝散聯閤化療治療乳腺癌的臨床療效。方法選擇2009年1月～2009年10月在我科住院治療的57例乳腺癌患者，隨機分成兩組，對照組按NP方案化療，治療組在化療的基礎上再給予柴鬍疏肝散治療。3週為1箇療程，至少治療2箇療程後評價和比較兩組的臨床療效、不良反應的髮生情況以及患者的預後。結果治療組乳腺癌軟組織轉移、肝轉移乳腺癌、肺轉移乳腺癌、骨轉移乳腺癌的治療有效率（RR）分彆為43.3%、6.7%、13.3%、3.3%；對照組的治療有效率（RR）依次分彆為29.6%、3.7%、7.4%、3.7%，治療組軟組織轉移乳腺癌與肺轉移乳腺癌治療有效率與對照組相比顯著升高，差異有統計學意義（P=0.046）。治療組白細胞減少、血紅蛋白降低、紅細胞減少以及血小闆減少的髮生率均顯著低于對照組，差異具有統計學意義（P<0.05）。兩組患者治療後6、12、18、24、30、36箇月的生存率比較，差異均無統計學意義（P>0.05）。結論柴鬍疏肝散NP方案治療乳腺癌能提高軟組織轉移乳腺癌與肺轉移乳腺癌的臨床療效，併減輕化療所緻的毒副反應，值得臨床推廣應用。
목적관찰시호소간산연합화료치료유선암적림상료효。방법선택2009년1월～2009년10월재아과주원치료적57례유선암환자，수궤분성량조，대조조안NP방안화료，치료조재화료적기출상재급여시호소간산치료。3주위1개료정，지소치료2개료정후평개화비교량조적림상료효、불량반응적발생정황이급환자적예후。결과치료조유선암연조직전이、간전이유선암、폐전이유선암、골전이유선암적치료유효솔（RR）분별위43.3%、6.7%、13.3%、3.3%；대조조적치료유효솔（RR）의차분별위29.6%、3.7%、7.4%、3.7%，치료조연조직전이유선암여폐전이유선암치료유효솔여대조조상비현저승고，차이유통계학의의（P=0.046）。치료조백세포감소、혈홍단백강저、홍세포감소이급혈소판감소적발생솔균현저저우대조조，차이구유통계학의의（P<0.05）。량조환자치료후6、12、18、24、30、36개월적생존솔비교，차이균무통계학의의（P>0.05）。결론시호소간산NP방안치료유선암능제고연조직전이유선암여폐전이유선암적림상료효，병감경화료소치적독부반응，치득림상추엄응용。
@@@@Objective To observe the clinical effects of Chaihu-Shugan-San integrated with chemotherapy in treatment of 57 patients with postoperative breast cancer. Methods Between January and October in 2009, 57 cases with postoperative breast cancer admitted in our department were randomly divided into two groups. The control group was treated with chemotherapy while the treating group was treated with Chaihu-Shugan-San integrated with chemotherapy. Three weeks as a course and after at leat two courses, the clinical effect, adverse reactions and prognosis were evaluated and compared. Results The RR of pa-renchyma metastatic breast cancer, hepatic metastatic breast cancer; lung metastatic breast cancer, bone metastatic breast cancer is 43.3%, 6.7%, 13.3%, 3.3% respectively in treating group, but is 29.6%, 3.7%, 7.4%, 3.7% respectively in the control group. There was significantly statistical difference in the RR of Parenchyma and lung metastatic breast cancer between two groups(P=0.046); the chance of decrease of WBC, hemoglobin reduce, decrease of RBC, platelet reduce in the treating group is lower than that of the control group, and difference also had statistical significance between two groups (P<0.05). There was no statistical meaning to compare the postoperative survival rate between two groups (P>0.05). Conclusion Chaihu-Shugan-San is worth being pro-moted, for it could lessen the toxic and side effects caused by the chemotherapy and improve the clinical effect.
